Acute renal failure in dense deposit disease: Complete recovery after combination therapy with immunosuppressant and plasma exchange

Clinical Nephrology

Volumn 75, Issue SUPPL. 1, 2011, Pages

  Krmar, R T ^a   Holtback U ^a   Linne T ^a   Berg, U B ^a   Celsi, G ^a   Soderberg M P ^a   Wernerson, A ^a   Szakos, A ^a   Larsson, S ^a   Skattum, L ^b   Barany P ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Complement alternative pathway; Dense deposit disease; Disease mechanisms; Factor H; Treatment

Indexed keywords

AZATHIOPRINE; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PREDNISOLONE;

ACUTE KIDNEY FAILURE; ADOLESCENT; ALLELE; ALOPECIA; ARTICLE; CASE REPORT; COMPLEMENT ALTERNATIVE PATHWAY; DENSE DEPOSIT DISEASE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC VARIABILITY; GLOMERULOPATHY; HEMATURIA; HUMAN; HYPOCOMPLEMENTEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; PLASMAPHERESIS; REGULATORY MECHANISM; REMISSION; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ADOLESCENT; BIOPSY; COMBINED MODALITY THERAPY; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR H; CYCLOPHOSPHAMIDE; DNA MUTATIONAL ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHYLPREDNISOLONE; MUTATION; PLASMA EXCHANGE; PULSE THERAPY, DRUG; TREATMENT OUTCOME;

EID: 79952000966     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CN106444     Document Type: Article

References (28)

1. Abrera-Abeleda MA, Nishimura C, Smith JL, Sethi S, McRae JL, Murphy BF, Silvestri G, Skerka C, Jozsi M, Zipfel PF, Hageman GS, Smith RJ. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet. 2006; 43: 582-589. (Pubitemid 44048765)
2. Boon CJ, van de Kar NC, Klevering BJ, Keunen JE, Cremers FP, Klaver CC, Hoyng CB, Daha MR, den Hollander AI. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol. 2009; 46: 1573-1594.
3. Cameron JS, Turner DR, Heaton J, Williams DG, Ogg CS, Chantler C, Haycock GB, Hicks J. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-termprognosis. Am J Med. 1983; 74: 175-192. (Pubitemid 13192172)
4. Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol. 1976; 116: 1-7.
5. de Jong PT. Age-related macular degeneration. N Engl J Med. 2006; 355: 1474-1485.
6. Dragon-Durey MA, Loirat C, Cloarec S, Macher MA, Blouin J, Nivet H, Weiss L, Fridman WH, Fremeaux-Bacchi V. Anti-Factor Hautoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2005; 16: 555-563. (Pubitemid 41725154)
7. Droz D, Nabarra B, Noel LH, Leibowitch J, Crosnier J. Recurrence of dense deposits in transplanted kidneys: I. Sequential survey of the lesions. Kidney Int. 1979; 15: 386-395.
8. Halling SF, Soderberg MP, Berg UB. Henoch Schonlein nephritis: clinical findings related to renal function and morphology. Pediatr Nephrol. 2005; 20: 46-51.
9. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003; 63: 1164-1177. (Pubitemid 36315601)
10. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis: evidence-based recommendations. Kidney Int. 1999 (Suppl.); 70: S33-S40.
11. Krmar RT, Berg UB. Long-term reproducibility of routine ambulatory blood pressure monitoring in stable pediatric renal transplant recipients. Am J Hypertens. 2005; 18: 1408-1414. (Pubitemid 41566666)
12. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta TS, Hageman GS, Immonen I, Meri S. Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol. 2007; 178: 3831-3836. (Pubitemid 46417652)
13. Leibowitch J, Halbwachs L, Wattel S, Gaillard MH, Droz D. Recurrence of dense deposits in transplanted kidney: II. Serum complement and nephritic factor profiles. Kidney Int. 1979; 15: 396-403.
14. Licht C, Schlotzer-Schrehardt U, Kirschfink M, Zipfel PF, Hoppe B. MPGN II - genetically determined by defective complement regulation? Pediatr Nephrol. 2007; 22: 2-9.
15. Magnusson KP, Duan S, Sigurdsson H, Petursson H, Yang Z, Zhao Y, Bernstein PS, Ge J, Jonasson F, Stefansson E, Helgadottir G, Zabriskie NA, Jonsson T, Bjornsson A, Thorlacius T, Jonsson PV, Thorleifsson G, Kong A, Stefansson H, Zhang K, Stefansson K, Gulcher JR. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 2006; 3: 5.
16. Nasr SH, Valeri AM, Appel GB, Sherwinter J, Stokes MB, Said SM, Markowitz GS, D'Agati VD. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients. Clin J Am Soc Nephrol. 2009; 4: 22-32.
17. Pickering MC, Cook HT. Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights fromhumans and animals. Clin Exp Immunol. 2008; 151: 210-230.
18. Rother U. A new screening test for C3 nephritis factor based on a stable cell bound convertase on sheep erythrocytes. J Immunol Methods. 1982; 51: 101-107. (Pubitemid 12125433)
19. Sanchez-Corral P, Gonzalez-Rubio C, Rodriguez de Cordoba S, Lopez-Trascasa M. Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol Immunol. 2004; 41: 81-84. (Pubitemid 38609399)
20. Sawanobori E, Umino A, Kanai H, Matsushita K, Iwasa S, Kitamura H, Oda T, Yoshizawa N, Sugita K, Higashida K. Aprolonged course of Group A streptococcus-associated nephritis: a mild case of dense deposit disease (DDD)? Clin Nephrol. 2009; 71: 703-707.
21. Seelen MA, Roos A, Wieslander J, Mollnes TE, Sjoholm AG, Wurzner R, Loos M, Tedesco F, Sim RB, Garred P, Alexopoulos E, Turner MW, Daha MR. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. J Immunol Methods. 2005; 296: 187-198. (Pubitemid 40174752)
22. Sjoholm AG. Complement components in normal serum and plasma quantitated by electroimmunoassay. Scand J Immunol. 1975; 4: 25-30.
23. Sjoholm AG. Complement components and complement activation in acute poststreptococcal glomerulonephritis. Int Arch Allergy Appl Immunol. 1979; 58: 274-284. (Pubitemid 9127676)
24. Skerka C, Lauer N,Weinberger AA, Keilhauer CN, Suhnel J, Smith R, Schlotzer-Schrehardt U, Fritsche L, Heinen S, Hartmann A,Weber BH, Zipfel PF. Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol. 2007; 44: 3398-3406. (Pubitemid 46678196)
25. Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Jozsi M. Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol. 2009; 46: 2801-2807.
26. Smith RJ, Alexander J, Barlow PN, Botto M, Cassavant TL, Cook HT, de Cordoba SR, Hageman GS, Jokiranta TS, Kimberling WJ, Lambris JD, Lanning LD, Levidiotis V, Licht C, Lutz HU, Meri S, Pickering MC, Quigg RJ, Rops AL, Salant DJ, Sethi S, Thurman JM, Tully HF, Tully SP, van der Vlag J,Walker PD,Wurzner R, Zipfel PF. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007; 18: 2447-2456. (Pubitemid 47378860)
27. Walker PD, Ferrario F, Joh K, Bonsib SM. Dense deposit disease is not a membranoproliferative glomerulonephritis. Mod Pathol. 2007; 20: 605-616. (Pubitemid 46788867)
28. Vaziri-Sani F, Holmberg L, Sjoholm AG, Kristoffersson AC, Manea M, Fremeaux-Bacchi V, Fehrman-Ekholm I, Raafat R, Karpman D. Phenotypic expression of factor H mutations in patients with atypical hemolytic uremic syndrome. Kidney Int. 2006; 69: 981-988. (Pubitemid 43372172)